Showing 4771-4780 of 5771 results for "".
- GlaxoSmithKline Takes $250 Million Stake in Vir as Companies Pair Up to Develop Coronavirus Treatmentshttps://modernod.com/news/glaxosmithkline-takes-250-million-stake-in-vir-as-companies-pair-up-to-develop-coronavirus-treatments/2477536/GlaxoSmithKline and Vir Biotechnology announced that they have agreed to enter into a collaboration to develop anti-viral antibodies for coronaviruses, including SARS-CoV-2. In addition, to gain access to Vir’s monoclonal antibody technology, GlaxoSmithKline said it will also make an equity
- Inovio Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Todayhttps://modernod.com/news/inovio-initiates-phase-1-clinical-trial-of-its-covid-19-vaccine-and-plans-first-dose-today/2477532/Inovio Pharmaceuticals announced that the FDA has accepted the company’s investigational new drug (IND) application for INO-4800, its DNA vaccine candidate designed to prevent COVID-19 infection, paving the way for phase 1 clinical testing of INO-4800 in healthy volunteers beginning this we
- ProtoKinetix AAGP Exhibits Efficacy and Safety in Model of Dry Eye Diseasehttps://modernod.com/news/protokinetix-aagp-exhibits-efficacy-and-safety-in-model-of-dry-eye-disease/2479530/ProtoKinetix, which recently announced filing for patent protection for new applications of its AAGP (PKX-001) molecule, announced preliminary results in efficacy and safety for use in treating dry eye disease (DED). PKX-001 demonstrated a protective effect in the murine model of dry eye d
- Incyte, Novartis to Evaluate JAK Inhibitor Ruxolitinib for Severe COVID-19 Patientshttps://modernod.com/news/incyte-novartis-to-evaluate-jak-inhibitor-ruxolitinib-for-severe-covid-19-patients/2477527/Incyte and Novartis announced that the companies plan to initiate a phase 3 collaborative study to assess ruxolitinib plus standard-of-care, versus standard care alone, in patients suffering from COVID-19-associated cytokine storm. The clinical trial will be sponsored by Incyte in the US, where t
- Provider Initiative to Help Ease Financial and Administrative Stress During Coronavirus Pandemichttps://modernod.com/news/provider-initiative-to-help-ease-financial-and-administrative-stress-during-coronavirus-pandemic/2477522/Humana announced a series of actions designed to help provide financial and administrative relief for the health care provider community facing the COVID-19 pandemic. First, Humana is implementing simplified and expedited claims processing in order to get reimbursement payments to provider
- China Gives Green Light to Allergan’s Xen Registration for the Surgical Management of Refractory Glaucomahttps://modernod.com/news/china-gives-green-light-to-allergans-xen-registration-for-the-surgical-management-of-refractory-glaucoma/2477514/Allergan announced China’s National Medical Products Administration (NMPA) approved the registration of Allergan’s Xen Gel Stent on March 26, 2020 for the surgical management of patients with refractory glaucoma. Xen is th
- SightGlass Vision Reports Positive Interim Data From Pivotal Clinical Trial of Novel Eyeglasses for Myopia Management in Childrenhttps://modernod.com/news/sightglass-vision-reports-positive-interim-data-from-pivotal-clinical-trial-of-novel-eyeglasses-for-myopia-management-in-children/2477515/SightGlass Vision announced topline results from a planned 12-month interim analysis of the company’s pivotal trial evaluating its novel eyeglasses designed to slow the progression of myopia in children. Data from the Control of Myopia Using Peripheral Diffusion Lenses: Efficacy and Safety
- Tatsuya Kaihara Appointed CEO of Santen Inc. and Head of North America Business of Santen Pharmaceuticalhttps://modernod.com/news/tatsuya-kaihara-appointed-ceo-of-santen-inc-and-head-of-north-america-business-of-santen-pharmaceutical/2477510/Santen announced the appointment of Tatsuya Kaihara as Corporate Officer and Head of North America Business of Santen Pharmaceutical. As of April 1, he is also appointed as CEO of Santen Inc. and he will lead the company’s North America business and report to Shigeo Taniuchi, P
- Mallinckrodt and Novoteris Receive Clearance from Health Canada to Start Pilot Trial of Inhaled Nitric Oxide Therapy for COVID-19https://modernod.com/news/mallinckrodt-and-novoteris-receive-clearance-from-health-canada-to-start-pilot-trial-of-inhaled-nitric-oxide-therapy-for-covid-19/2477506/Mallinckrodt and Novoteris announced that the Therapeutic Products Directorate of Health Canada has cleared the companies’ joint pilot clinical trial, entitled “Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung
- Allergan COVID-19 Response: Program Enhancementshttps://modernod.com/news/allergan-covid-19-response-program-enhancements/2477507/Allergan has announced several program enhancements designed to assist eye care professionals and patients during the COVID-19 pandemic. These include: Lowering copay savings card offerings for Restas